{
    "eid": "2-s2.0-85120038365",
    "title": "Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients",
    "cover-date": "2022-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Pharmacology, Toxicology and Pharmaceutics (all)",
            "@code": "3000",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Atazanavir",
        "Pharmacogenetics",
        "Population Pharmacokinetics",
        "Ritonavir",
        "Thai patient"
    ],
    "authors": [
        "Noppaket Singkham",
        "Anchalee Avihingsanon",
        "Richard C. Brundage",
        "Angela K. Birnbaum",
        "Narukjaporn Thammajaruk",
        "Kiat Ruxrungtham",
        "Torsak Bunupuradah",
        "Sasisopin Kiertiburanakul",
        "Ploenchan Chetchotisakd",
        "Baralee Punyawudho"
    ],
    "citedby-count": 0,
    "ref-count": 56,
    "ref-list": [
        "Guidelines for the use of antiretroviral agents in adults and adolescents with HIV",
        "Atazanavir: a review of its use in the management of HIV-1 infection",
        "Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir",
        "Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors",
        "Pharmacokinetic enhancers in HIV therapeutics",
        "Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy",
        "Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection",
        "PharmGKB summary: very important pharmacogene information for CYP3A5",
        "Genetic contribution to variable human CYP3A-mediated metabolism",
        "A population pharmacokinetic-pharmacogenetic analysis of atazanavir",
        "Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients",
        "Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors",
        "Influence of CYP3A5 and SLCO1B1 polymorphisms on atazanavir/r concentrations in Thai HIV-infected patients",
        "Impact of genetic polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical implications: update of the literature",
        "Role and modulation of drug transporters in HIV-1 therapy",
        "Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C\u2013>T polymorphism at the multidrug resistance gene 1",
        "Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia",
        "Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms",
        "Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia",
        "CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children",
        "Nuclear receptor PXR, transcriptional circuits and metabolic relevance",
        "Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C\u2192 T) with reduced concentrations of unboosted atazanavir",
        "Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance",
        "Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring",
        "Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients",
        "Evaluation of boosted and unboosted atazanavir plasma concentration in HIV infected patients",
        "Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients",
        "Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients",
        "Factors influencing lopinavir and atazanavir plasma concentration",
        "Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS clinical trials group study A5202",
        "Pharmacokinetic-pharmacodynamic modeling of unboosted atazanavir in a cohort of stable HIV-infected patients",
        "The pharmacogenetics of HIV treatment: a practical clinical approach",
        "Genetic polymorphisms affecting the pharmacokinetics of antiretroviral drugs",
        "A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults",
        "Low-dose ritonavir-boosted atazanavir (200/100 mg) maintained a high virological efficacy up to 4 years in treatment-experienced HIV-1 infected adults: a prospective cohort study from Asia",
        "Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial",
        "The international interlaboratory quality control program for measurement of antiretroviral drugs in plasma: a global proficiency testing program",
        "QIAamp\u00ae DNA mini and blood mini handbook [internet]",
        "Allelic discrimination using fluorogenic probes and the 5\u2032 nuclease assay",
        "Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose",
        "Xpose\u2013an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM",
        "Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance",
        "Model appropriateness and population pharmacokinetic modeling",
        "A new equivalence based metric for predictive check to qualify mixed-effects models",
        "Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers",
        "Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients",
        "Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies",
        "Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients",
        "Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients",
        "Sex differences in pharmacokinetics and pharmacodynamics",
        "Antiretroviral pharmacokinetic profile: a review of sex differences",
        "Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin",
        "Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects",
        "Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS clinical trials group (ACTG) PEARLS study (NWCS 342)"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Phayao",
            "@id": "60114221",
            "affilname": "University of Phayao",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60114221",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60031780",
            "affilname": "Thai Red Cross Agency",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031780",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Khon Kaen",
            "@id": "60026046",
            "affilname": "Faculty of Medicine, Khon Kaen University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026046",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60015887",
            "affilname": "Faculty of Medicine Ramathibodi Hospital, Mahidol University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015887",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Minneapolis",
            "@id": "60015427",
            "affilname": "College of Pharmacy",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015427",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Chaing Mai",
            "@id": "60000881",
            "affilname": "Chiang Mai University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000881",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Chiang Mai University",
        "Thailand Research Fund"
    ]
}